Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies
about
HIV-1 superinfection in women broadens and strengthens the neutralizing antibody responseCD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristicsIdentification of the cellular prohibitin 1/prohibitin 2 heterodimer as an interaction partner of the C-terminal cytoplasmic domain of the HIV-1 glycoproteinTenascin-C is an innate broad-spectrum, HIV-1-neutralizing protein in breast milkA lectin isolated from bananas is a potent inhibitor of HIV replicationPolyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individualsScaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide componentA Blueprint for HIV Vaccine DiscoveryHIV-1 neutralizing antibodies: understanding nature's pathwaysMixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvantsSiglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosidesHuman Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus MacaquesSialyllactose in viral membrane gangliosides is a novel molecular recognition pattern for mature dendritic cell capture of HIV-1HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunizationIncreased Immunogenicity of a DNA-Launched Venezuelan Equine Encephalitis Virus-Based Replicon DNA VaccineAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesCrystal Structure of the Neutralizing Llama VHH D7 and Its Mode of HIV-1 gp120 InteractionCrystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1Conserved structural elements in the V3 crown of HIV-1 gp120Antibody 2G12 Recognizes Di-Mannose Equivalently in Domain- and Nondomain-Exchanged Forms but Only Binds the HIV-1 Glycan Shield if Domain ExchangedCrystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41Crystal Structure of HIV-1 Primary Receptor CD4 in Complex with a Potent Antiviral AntibodySolution Structure of the Monovalent Lectin Microvirin in Complex with Man (1-2)Man Provides a Basis for Anti-HIV Activity with Low ToxicitySequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 BindingDesigned oligomers of cyanovirin-N show enhanced HIV neutralizationFocused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep SequencingComplex-type N-glycan recognition by potent broadly neutralizing HIV antibodiesA Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan ShieldBroad and potent neutralization of HIV-1 by a gp41-specific human antibodyViral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization BreadthA gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen RecognitionSomatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 NeutralizationFunctional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individualsBroadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding GlycansSupersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16Structure-Based Design, Synthesis, and Characterization of Dual Hotspot Small-Molecule HIV-1 Entry InhibitorsHeavy Chain-Only IgG2b Llama Antibody Effects Near-Pan HIV-1 Neutralization by Recognizing a CD4-Induced Epitope That Includes Elements of Coreceptor- and CD4-Binding SitesThermodynamic Signatures of the Antigen Binding Site of mAb 447–52D Targeting the Third Variable Region of HIV-1 gp120Structure of the Fusion Core and Inhibition of Fusion by a Heptad Repeat Peptide Derived from the S Protein of Middle East Respiratory Syndrome Coronavirus
P2860
Q21090490-FA915E0F-C456-45C4-A5EE-DF7103A4704EQ21090521-FAEDDA37-6168-4119-8097-C964FCE63766Q24316304-7AE0B133-D157-4EC4-A282-88DE45318A6BQ24598653-E0E3884A-74CE-438E-8F58-4FD2F9E28577Q24629155-1C8B7DD3-5F54-4DCB-A8C5-0C8B0A727485Q24635002-71FC5049-448D-4B56-980A-F32500DC852BQ24650458-EABD78DC-9257-4DFE-BFC6-C4F6D4ACB6ECQ26829865-1FB77BF8-6690-459B-BDDE-580FD26B185DQ27000480-5FFC9F97-A94D-4AC6-A516-07469900E412Q27304735-DD908175-9950-4BF7-9093-CE26FEB1AEBAQ27318429-2CFC1510-EF81-415D-8E12-EAC885A9C410Q27318508-2F3D0C4B-C826-439A-AC73-7DE8661D5CD7Q27319569-7F39F6FB-35B7-4055-A15A-176DB864CCBEQ27324184-DDFB2163-12CC-40DD-B9D2-58F4F89B85C0Q27485003-4DE50FCE-1B02-4EBF-BBAF-B1C75980EE4AQ27489000-651ADAC8-FC07-4587-A676-6838737DA9D6Q27661588-52CA9689-494D-4CCE-B36A-83A3EC7A01E4Q27662167-918E26AE-AFDE-460B-A55A-7C7D0AA50A3BQ27663325-CCA17C59-3F1B-4F72-A069-A67BBB089418Q27664038-AD9B1979-6BBC-4AF3-9862-76E7A65659B5Q27666159-9A9AB51B-7418-418A-9EE8-3F1EBC44D787Q27666197-DD794D3F-6429-410E-9245-7A78310EE33BQ27667444-3814D367-1128-402C-A603-15554D128693Q27670829-2C338553-CB93-489F-9A1B-9908DAAC3060Q27671182-C95E31D2-BE89-4543-B14F-2D9EC5A165AFQ27671696-225680C5-13F8-4F51-B1BA-7752EBCA6975Q27674878-5BB0BDDF-FE43-4258-810D-30CE282DF597Q27675032-D03FD135-0723-4ECC-A1A5-C8D2249D7E7CQ27675131-8CDD1432-F802-45A1-9A81-31BBC5288258Q27676728-1E290EE4-9E8E-4C03-8A4D-BD0757360011Q27676864-D3DE6EDE-3D27-4C6F-83DB-D6CFA678EC31Q27677117-FE71488A-A47C-430B-882E-902F977885CFQ27677941-15226E83-497A-44F0-BC93-C39D3E497040Q27678062-2078D942-7FE0-4A76-8916-266534FD7871Q27678306-8EFB04EC-4DA6-41F9-B3C1-1F3DC2F6D36BQ27678312-69F98B41-EAAB-4D14-892E-737072B76EF8Q27678493-86A97A5B-78F9-4299-B678-F86620DF06BBQ27679031-648BA298-997A-436C-AB34-2CE3B193304BQ27679559-0841B8EE-ACFF-4B1E-93BD-149AD8D5B046Q27680061-88E1E2CD-3F06-4647-98E9-E31C1336AF43
P2860
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Human immunodeficiency virus t ...... icited neutralizing antibodies
@ast
Human immunodeficiency virus t ...... icited neutralizing antibodies
@en
type
label
Human immunodeficiency virus t ...... icited neutralizing antibodies
@ast
Human immunodeficiency virus t ...... icited neutralizing antibodies
@en
prefLabel
Human immunodeficiency virus t ...... icited neutralizing antibodies
@ast
Human immunodeficiency virus t ...... icited neutralizing antibodies
@en
P2093
P2860
P3181
P1433
P1476
Human immunodeficiency virus t ...... icited neutralizing antibodies
@en
P2093
Goepfert P
Koutsoukos M
P2860
P304
P3181
P356
10.1128/JVI.79.16.10108-10125.2005
P407
P577
2005-08-01T00:00:00Z